What is the recommended treatment for an adult exposed to pertussis (whooping cough)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Exposure to Pertussis in an Adult

For adults exposed to pertussis, administer azithromycin 500 mg on day 1, followed by 250 mg daily on days 2-5 as post-exposure prophylaxis, regardless of vaccination status. 1

Post-Exposure Prophylaxis Regimen

The Centers for Disease Control and Prevention recommends the same antimicrobial agents and dosing regimens for post-exposure prophylaxis as are used for active treatment. 1 For adults, this means:

  • Azithromycin: 500 mg on day 1, then 250 mg daily for days 2-5 1
  • Alternative if macrolide contraindicated: Trimethoprim-sulfamethoxazole (TMP-SMZ) for patients with macrolide allergies or contraindications 1

Timing and Rationale for Prophylaxis

  • Prophylaxis should be administered within 21 days of exposure to the pertussis case 1, 2
  • The primary goal is to eradicate Bordetella pertussis from the nasopharynx and prevent transmission, not necessarily to prevent infection in the exposed individual 3
  • Pertussis remains highly contagious with secondary attack rates exceeding 80% among susceptible household contacts 3, 2
  • Vaccinated individuals can still develop breakthrough infections and transmit disease to others, making prophylaxis essential regardless of vaccination status 3

Priority Populations for Prophylaxis

Prophylaxis is especially critical when the exposure setting includes:

  • Infants <12 months of age 1
  • Women in the third trimester of pregnancy 1
  • Healthcare workers with known exposure 1
  • All household and close contacts, regardless of age and vaccination status 3, 2

Important Considerations and Precautions

  • Macrolide contraindications: Do not use in patients with history of hypersensitivity to any macrolide agent 1
  • Drug interactions: Azithromycin should not be taken simultaneously with aluminum- or magnesium-containing antacids as they reduce absorption 1
  • QTc prolongation risk: Obtain baseline ECG before initiating azithromycin in patients taking medications that prolong QTc interval (such as citalopram), and repeat ECG at 1 month if baseline is normal 1
  • Cytochrome P450 interactions: Erythromycin and clarithromycin (but NOT azithromycin) inhibit the cytochrome P450 enzyme system and can interact with other drugs metabolized by this pathway 1

Isolation and Infection Control

  • If the exposed adult develops symptoms and begins antibiotic treatment, they should isolate at home and away from work for 5 days after starting antibiotics 1, 3
  • If antibiotics cannot be administered to a symptomatic individual, isolation should continue for 21 days after cough onset 3
  • Respiratory droplet precautions are required in healthcare settings until 5 days of appropriate antibiotic treatment are completed 3, 2

Why Azithromycin is Preferred

  • Azithromycin has equal efficacy to erythromycin for pertussis treatment and prophylaxis 1
  • Superior tolerability with milder and less frequent side effects compared to erythromycin 1
  • Significantly higher completion rates: 93% with azithromycin versus 57% with erythromycin, primarily due to fewer gastrointestinal side effects 4
  • Shorter treatment duration (5 days vs 14 days) improves compliance 4
  • Superior pharmacokinetics with longer tissue half-lives support shorter treatment courses 1

Common Pitfalls to Avoid

  • Do not delay prophylaxis while waiting for laboratory confirmation of the index case—begin immediately upon clinical suspicion 1
  • Do not assume vaccination provides complete protection—immunity wanes 5-10 years after vaccination, and breakthrough infections occur regularly 3
  • Do not limit prophylaxis to unvaccinated contacts—all close contacts require prophylaxis regardless of vaccination status 3
  • Do not use adjunctive therapies such as β-agonists, antihistamines, corticosteroids, or pertussis immunoglobulin, as these have no proven benefit 1, 3

Vaccination Status Update

  • Verify the exposed adult's vaccination history and ensure they have received Tdap booster if not previously administered 1
  • Adults 19-64 years should receive a single dose of Tdap if not previously vaccinated 1
  • Vaccine immunity wanes after 5-10 years, making previously vaccinated individuals susceptible to infection 1

References

Guideline

Treatment of Pertussis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment and Management of Pneumonia and Pertussis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pertussis Infection Risk and Management in Fully Vaccinated Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.